Prof Owen Bowden-Jones
Day Two – Club Drug and Novel Psychoactive Substances
Prof Owen Bowden-Jones is a Consultant in Addiction Psychiatry at the CNWL Club Drug Clinic, London UK and an Honorary Professor at University College London.
Owen is the Chair of the Advisory Council on the Misuse of Drugs (ACMD), a statutory body which provides advice to the UK Government on drugs and drug harms. He is also national clinical adviser to the Alcohol, Drugs and Tobacco division, Public Health England and a member of the Board of Trustees at the Society on the Study of Addiction (SSA). His research interests include emerging drugs harms, particularly in young people, and sexualize drug use.
In 2010, Owen founded the CNWL Club Drug Clinic, an innovative service offering treatment for emerging drug problems such as the use of novel psychoactive substance, club drugs and online purchased prescription medications.
He led the development and publication of the national NEPTUNE clinical guidance and associated e-learning for emerging illicit drugs. The NEPTUNE project was a finalist at the 2018 Health Service Journal awards.
Owen contributes widely to the public debate on substance use in the UK and authored ‘The Drug Conversation’, a book for parents about adolescent drug use. The book was ‘Highly Commended’ at the BMA Book Awards.
Prof Sam Chamberlain
Day One – Behavioural Addictions
Sam Chamberlain is Professor of Psychiatry at the Department of Psychiatry, University of Southampton.
Prof Chamberlain’s research and clinical work focuses on the neurobiology and treatment of impulsive, compulsive, and behaviourally-addictive disorders. In particular, this involves three main aims: (1) developing and validating clinical tools; (2) measuring cognitive problems and brain circuits that contribute (including vulnerability markers); and (3) improving existing treatments and developing new ones.
More recently he has been involved in large-scale population research examining the effects of the Covid-19 pandemic and lockdown on mental health (including impulsive-compulsive symptoms), and cognitive deficits associated with “long Covid”.
Prof Chamberlain leads the knowledge arm of the EU Cost Action Network for Problematic Usage of the Internet; and is Co-Founder of the National UK Research Network on Behavioural Addictions (NUK-BA).
He is co-author of the following books: Clinical Guide to Obsessive Compulsive and Related Disorders (Oxford University Press), Why Can't I Stop? Reclaiming Your Life from a Behavioral Addiction (Johns Hopkins University Press), and Obsessive-Compulsive Personality Disorder (American Psychiatric Association Publishing). Prof Chamberlain’s peer-reviewed research articles have appeared in Science, JAMA Psychiatry, the American Journal of Psychiatry, the British Journal of Psychiatry, and Biological Psychiatry.
Prof Elizabeth Elliott AM
Day Two - Fetal Alcohol Spectrum Disorders
Elizabeth Elliott AM FAHMS FRSN is a Professor of Paediatrics at the University of Sydney. She heads the NSW FASD Assessment Service within CICADA - the service for Care and Intervention for Children and Adolescents Affected by Drugs and Alcohol, in the Sydney Children's Hospitals Network. Elizabeth is Co-Director of the NHMRC Centre for Research Excellence in FASD, and jointly led development of the Australian Guide to the Diagnosis of FASD, the FASD Hub, and the FASD Register.
She is involved in several pregnancy cohort studies, which include inquiry into 3D facial imaging and epigenetics. In remote Aboriginal communities she was invited to conduct prevalence, treatment, and longitudinal follow-up studies in FASD. She Co-Chairs the National FASD Advisory Group, is a Member of the NOFASD Board, and was involved in the successful 2020 campaign for pregnancy warning labels for Australian alcohol.
Prof Shelly Greenfield
Day Three - Gender Differences in Substance Use Disorders: Implications for Women’s Addiction Treatment
Shelly F. Greenfield, MD, MPH is Professor of Psychiatry at Harvard Medical School and the Kristine M. Trustey Endowed Chair of Psychiatry at McLean Hospital where she also serves as the Chief Academic Officer. She is the Chief of the Division of Women's Mental Health and the Director of Clinical and Health Services Research and Education in the Alcohol, Drug and Addiction Treatment Program at McLean Hospital.
Dr Greenfield is an addiction psychiatrist, clinician and researcher. Dr Greenfield has served as Principal Investigator and Co-Investigator on federally funded research focusing on treatment for substance use disorders, gender differences in substance disorders, and health services for substance disorders.
She received a National Institute on Drug Abuse (NIDA)-funded career award in substance use disorder patient oriented research (2005-2016).
Funded by grants from NIH/NIDA, she developed and tested a new manual-based group therapy for women with substance use disorders, the Women’s Recovery Group (WRG). The WRG is an evidence-based treatment and the manual for dissemination was published in 2016, Treating Women with Substance Use Disorders: The Women’s Recovery Group Manual. She is immediate Past President of the American Academy of Addiction Psychiatry and current member and past chair of the American Psychiatric Association's Council on Addiction Psychiatry. She is immediate past Editor-in-Chief of the Harvard Review of Psychiatry, a position in which she served for 16 years (2002-2018). Dr. Greenfield was a member of the Advisory Committee on Services for Women for the U.S. Substance Abuse and Mental Health Services Administration (2011-2017). She has been elected to the American College of Psychiatrists and the College on Problems of Drug Dependence, and is a Distinguished Fellow of the American Psychiatric Association. She received the R. Brinkley Smithers Distinguished Scientist Award from the American Society of Addiction Medicine and the A. Clifford Barger Award for Excellence in Mentoring from Harvard Medical School.
Prof Dan Lubman AM
Day Two - RACP Professor John Caughey Oration
The Australian Addiction Field; Past Present and Future
Professor Dan Lubman has worked across mental health and drug treatment settings in both the UK and Australia. He is Director of Turning Point, Australia's leading national addiction treatment, research and education centre, inaugural Director of the Monash Addiction Research Centre and Professor of Addiction Studies and Services at Monash University. Dr Lubman's research is wide-ranging and includes investigating the harms associated with alcohol, drugs and gambling, the impact of alcohol and drug use on brain function, the relationship between substance use, gambling and mental disorder, as well as the development of targeted telephone, online and face-to-face intervention programs within community, school, primary care, mental health and drug treatment settings.
Dr Lubman has published over 500 major reports, peer-reviewed scientific papers and book chapters, and was Chair of the Royal Australian and New Zealand College of Psychiatrists' (RANZCP) Faculty of Addiction Psychiatry for over a decade. He is regularly contacted for policy advice and community comment, and sits on multiple government expert committees. He has received numerous awards, including the Senior Scientist Award from the Australasian Professional Society on Alcohol and Other Drugs, as well as the RANZCP Senior Research Award.